Drug Profile
Research programme: obesity therapy - TME Pharma
Alternative Names: NOX-B11Latest Information Update: 01 Aug 2022
Price :
$50
*
At a glance
- Originator NOXXON Pharma AG
- Developer TME Pharma
- Class Nucleotide aptamers
- Mechanism of Action Ghrelin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in Germany
- 14 Aug 2009 Preclinical development is ongoing in Germany
- 24 Mar 2006 NOXXON Pharma and Pfizer have entered into an exclusive worldwide agreement to develop NOX-B11 for obesity